Shaily Engineering PlasticsQ4 FY24

Shaily Engineering Plastics Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,086.4P/E: 69.7Market Cap: ₹14.2K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

No

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Pharma segment expected to grow at 50%-60% in the current year (FY '25).
  • Overall volume of pens/devices anticipated to increase from ~11 million in FY '24 to around 17-18 million in FY '25, reflecting 15%-16% growth.
  • Capacity utilization currently around 40%, expected to increase as new business scales up.
  • Plans to ramp up pen/device volumes gradually with approvals on proprietary platforms like Teriparatide and Liraglutide anticipated in FY '25.
  • Additional capex of $15-$20 million planned over the next 6-7 years to expand capacity from current 25-30 million devices per year to ~60-70 million.
  • Revenue growth expected from increasing proportion of proprietary devices (currently shifting from 10% to ~30-40% of value).
  • Consumer segment faced a degrowth of ~4% due to raw material pass-through and lower toy sales but base business expected to grow 12%-15%.
  • Shaily UK revenue to be back-ended with more growth expected in H2 FY '25.

See what Shaily Engineering Plastics management said on margin guidance — free account, 30 seconds.

Fundraise plans

No
  • There is no expectation for significant new fundraising through debt or equity in the near term.
  • The company has already made a substantial capex investment last year, creating infrastructure to handle production capacity up to 60-70 million devices annually.
  • Additional capex of $15-20 million may be needed to scale from 25-30 million to 70 million devices, but this is planned over the next 6-7 years, not the next 2-3 years.
  • The management does not foresee the need for large-scale fundraising (e.g., $50-100 million) for semaglutide or other programs.
  • The focus is on improving capacity utilization and organic growth rather than immediate capital raising.
  • No substantial capex or capital raising is planned for FY25; only minor capex will be undertaken to improve utilization.

See what Shaily Engineering Plastics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • No substantial capex is planned immediately; only small capexes are expected in FY25.
  • Focus currently is on improving utilization of existing capacity rather than large new investments.
  • A previous large capex was done last year to create infrastructure supporting up to 60-70 million devices annually.
  • Installed equipment currently supports 25-30 million devices per year; additional machinery will be added as approvals and scale-up occur.
  • Future additional capex of around $15-20 million may be required to expand capacity from 30 million to 70 million devices, but this is not expected within the next 2-3 years; envisioned over 6-7 years.
  • Capex for semaglutide-related scale-up is expected to be lower due to location in India and existing infrastructure.
  • The company is managing growth and capacity expansion prudently without aggressive capital investment in the near term.

Track Shaily Engineering Plastics — get its next earnings analysis in your feed

How does Shaily Engineering Plastics rank vs peers in Consumer Durables?

Pro feature
ThisShaily Engineering Plastics
Rev 3Mar 3

How does Shaily Engineering Plastics rank in Consumer Durables?

Compare Shaily Engineering Plastics against every Consumer Durables company (Q4 FY24) on revenue, margins and earnings-call signals.

View Consumer Durables leaderboard →

Others in Consumer Durables this season

  • Arham Tech (Q2 FY27)

    Revenue from Operations for H1FY27: ₹85.48 Crores, an 87.34% year-on-year increase from ₹45.63 Crores in H1FY26 (Page 30, 29). Key investor presentation takeawa

  • Khazanchi Jewell (Q2 FY27)

    Q2 FY27 revenue from operations: ₹605.58 Crore, up 10.4% YoY (Q2 FY26: ₹548.60 Crore) [Page 7] . Key investor presentation takeaways from Khazanchi Jewellers Lt

  • Uday Jewellery (Q2 FY27)

    Q2 FY27 Total Income: ₹210.46 crore, up 30% year-on-year (YoY) . Key results statement takeaways from Uday Jewellery Industries Ltd's Q2 FY27 results statement

  • Rajesh Exports (Q2 FY27)

    Revenue from operations (net sales) for the quarter ended 30/09/2026: ₹2,895.85 million. Key results statement takeaways from Rajesh Exports Ltd's Q2 FY27 resul

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →